Oral Antidiabetic Drugs Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Oral Antidiabetic Drugs Market By 2029?

The oral antidiabetic drug market has experienced substantial growth in recent times. This market is expected to increase from $62.25 billion in 2024 to $66.73 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. Historically, this expansion can be ascribed to the escalating prevalence of diabetes, enhanced understanding of diabetes management, an increase in the elderly population, improved access to advanced oral antidiabetic formulations, and the development of healthcare infrastructure.

The oral antidiabetic drugs market is projected to experience substantial expansion in the coming years, with its size forecast to reach $86.92 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period is primarily driven by factors such as the increasing adoption of innovative oral antidiabetic therapies, a surge in investments towards diabetes research and development, a heightened demand for economical diabetes treatments, the escalating global prevalence of type 2 diabetes, and a growing emphasis on personalized medicine within diabetes care. Furthermore, significant trends anticipated during this period include advancements in drug delivery technologies, innovations in combination therapies, the integration of digital health tools for diabetes management, the development of safer and more effective oral antidiabetic drugs, and progress in personalized treatment strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

Which Factors And Drivers Are Influencing The Oral Antidiabetic Drugs Market In 2025?

The growing prevalence of type 2 diabetes is anticipated to drive expansion in the oral antidiabetic drugs market in the future. Type 2 diabetes is a chronic ailment where the body either resists insulin or fails to produce enough to maintain normal glucose levels. The rise in this condition is attributable to increasing obesity rates, as excess body fat contributes to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs aid in managing type 2 diabetes by enhancing insulin sensitivity, boosting insulin secretion, or reducing glucose production and absorption, thereby helping to maintain optimal blood sugar levels. For instance, the Office for Health Improvement and Disparities, a UK-based government agency, reported in March 2025 that the prevalence of type 2 diabetes in adults aged 17+ in England climbed to 7.0%, an increase from 6.8% in March 2023. This escalating incidence of type 2 diabetes is thus propelling the growth of the oral antidiabetic drugs market.

What Are The Segment Types Shaping The Oral Antidiabetic Drugs Market?

The oral antidiabetic drugs market covered in this report is segmented –

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Sublingual, Buccal

3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:

1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

5) By Thiazolidinediones: Pioglitazone, Rosiglitazone

6) By Meglitinides: Repaglinide, Nateglinide

7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

8) By Other Drug Classes: Bromocriptine, Colesevelam

What Long-Term Trends Will Shape The Future Growth Of The Oral Antidiabetic Drugs Industry?

Companies operating within the oral antidiabetic drugs market are concentrating on clinical trials to develop more effective and safer treatment options, broaden their product portfolios, and secure regulatory approvals for next-generation therapies. Clinical trials are controlled research studies conducted with human participants to assess the safety, effectiveness, and side effects of new medical treatments, drugs, or interventions. For example, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, launched Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist designed to streamline diabetes management through successful phase 3 trial. This oral therapy aims to provide comparable efficacy and safety to injectable alternatives while improving patient adherence. In clinical trials, orforglipron decreased HbA1c (a marker of blood sugar control) by an average of 1.3% to 1.6% across various doses over 40 weeks.

Which Industry Leaders Are Driving Innovation Across The Oral Antidiabetic Drugs Market?

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Oral Antidiabetic Drugs Market?

North America was the largest region in the oral antidiabetic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oral Antidiabetic Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25854&type=smp

Browse Through More Reports Similar to the Global Oral Antidiabetic Drugs Market 2025, By The Business Research Company

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795